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Epicardial adipose tissue (EAT) has been proposed as a cardiometabolic and hepatic fibro-
sis risk factor in patients with non alcoholic fatty liver disease (NAFLD). Aim of this study
was to evaluate the role of EAT in NAFLD by analyzing 1) the association between EAT, the
other metabolic parameters and the severity of steatosis 2) the relationship between cardio-
vascular (cIMT, cplaques, E/A), liver (presence of NASH and significant fibrosis) damage
and metabolic risk factors including EAT 3) the relationship between EAT and genetic fac-
tors strongly influencing liver steatosis.
Methods
In a cross-sectional study, we considered 512 consecutive patients with NAFLD (confirmed
by biopsy in 100). EAT, severity of steatosis, carotid intima-media thickness (cIMT) and pla-
ques were evaluated by ultrasonography and results analysed by multiple linear and logistic
regression models. Variables independently associated with EAT (mm) were female gender
(p = 0.003), age (p = 0.001), BMI (p = 0.01), diastolic blood pressure (p = 0.009), steatosis
grade 2 (p = 0.01) and 3 (p = 0.04), fatty liver index (p = 0.001) and statin use (p = 0.03).
Variables independently associated with carotid IMT were age (p = 0.0001), hypertension
(p = 0.009), diabetes (p = 0.04), smoking habits (p = 0.04) and fatty liver index (p = 0.02),
with carotid plaques age (p = 0.0001), BMI (p = 0.03), EAT (p = 0.02),) and hypertension
(p = 0.02), and with E/A age (p = 0.0001), diabetes (p = 0.005), hypertension (p = 0.04) and
fatty liver index (p = 0.004). In the 100 patients with available liver histology non alcoholic
steatohepatitis (NASH) was independently associated with EAT (p = 0.04) and diabetes
(p = 0.054) while significant fibrosis with EAT (p = 0.02), diabetes (p = 0.01) and waist
PLOS ONE | DOI:10.1371/journal.pone.0162473 September 14, 2016 1 / 19
a11111
OPENACCESS
Citation: Fracanzani AL, Pisano G, Consonni D,
Tiraboschi S, Baragetti A, Bertelli C, et al. (2016)
Epicardial Adipose Tissue (EAT) Thickness Is
Associatedwith Cardiovascular and Liver Damage in
NonalcoholicFatty Liver Disease. PLoS ONE 11(9):
e0162473. doi:10.1371/journal.pone.0162473
Editor:Giovanni Targher, Universita degli Studi di
Verona, ITALY
Received: June 3, 2016
Accepted:August 23, 2016
Published:September 14, 2016
Copyright:© 2016 Fracanzani et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricteduse, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement:All relevant data are
within the paper and its Supporting Information files.
Funding: The authors received no specific funding
for this work.
Competing Interests: The authors have declared
that no competing interests exist.
circumference (p = 0.05). No association between EAT and PNPLA3 and TM6SF2 polymor-
phisms was found.
Conclusion
In patients with NAFLD, EAT is associated with the severity of liver and vascular damage
besides with the known metabolic risk factors.
Introduction
Nonalcoholic fatty liver disease (NAFLD) represents an emerging public health problem
worldwide. Indeed, it has reached epidemic proportions and is now the most common liver
disease inWestern Countries, affecting 20%–34% of the general population[1–3].
NAFLD is considered the hepatic manifestation of the metabolic syndrome (MS), as hepatic
fat accumulation is a consequence of systemic insulin resistance and hyperinsulinemia
although recently it has been proposed that NAFLD may precedemetabolic syndrome [4].
Therefore, NAFLD is strongly associated with and is an independent predictor of cardiovascu-
lar diseases, including coronary heart disease and stroke[3, 5], which have been reported to be
the first cause of death[6–8].
However the heritability can only partially explain the predisposition to progressive atheroscle-
rotic damage in NAFLD. The I148M variant of patatin-like phospholipase domain-containing-3
(PNPLA3) gene which is involved in lipid remodeling, is actually defined as themajor common
genetic determinant of NAFLD and it is associatedwith progression to NASH [9], while its role in
atherosclerotic damage has so far been reported only in young patients with NAFLD[10].
Ectopic fat accumulation within and around visceral organs such as liver and heart, and in
particular epicardial fat [11, 12], considered the best marker of intra-myocardial fat accumula-
tion for its direct contiguity to myocardium[13, 14], is associated to an increased cardiovascu-
lar risk [13, 15]. Indeed, EAT thickness has been reported to predict coronary artery disease,
left ventricular dysfunction, and atrial fibrillation [13, 15, 16]
Furthermore, EAT may play a pivotal role in the development and progression of both dia-
stolic and systolic heart failure[17–19]. It is possible that epicardial adipose tissue (EAT) which
secretes vasoactivemolecules that regulate coronary arterial tone, and modulate inflammation
[20–24], interferes with the autonomic nervous system determining both cardiovascular and
liver damage [25, 26].
A robust association between EAT, the degree of fatty liver and early atherosclerotic damage
has been reported only in obese patients with NAFLD either of adult or pediatric age [27, 28].
In addition, EAT was recently correlated with arterial stiffness and liver fibrosis in NAFLD
patients [29, 30]. However studies in large cohorts of patients with NAFLD confirming these
observations are not available.
Thus, we conducted this study with the aim to evaluate 1) the association between EAT, the
other metabolic parameters and the severity of steatosis 2) the relationship between cardiovas-
cular (cIMT, cplaques, E/A), liver (presence of NASH and significant fibrosis) damage and
metabolic risk factors including EAT and 3) the relationship between EAT and genetic factors
strongly influencing liver steatosis, including PNPLA3 and TMS6SF2.
Methods
A cross-sectional study was performed. From May 2013 to June 2014 we enrolled 512 consecu-
tive subjects with diagnosis of NAFLD, done at enrolment by ultrasonography and confirmed
EAT in NAFLD
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by biopsy in 100. Two hundred and eighteen patients were diagnosed at the IRCCSCa’ Granda,
Metabolic Liver Disease outpatient service, and 294 at the Bassini Hospital from a cohort stud-
ied for the prevention of dyslipidemia and cardiovascular disease.
Subjects with viral B and C hepatitis, Wilson's disease, a1-antitrypsin deficiency, autoim-
mune hepatitis, genetic hemochromatosis, and subjects using drugs potentially causing steato-
sis were excluded from the study.
Subjects were also excluded from this study if a history of cardiovascular disease (CVD)
(myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)was
recorded.
A complete evaluation of anthropometric, clinical, biochemical parameters was collected at
enrollment in the entire cohort of NAFLD including 512 patients. Of these 100 had liver histol-
ogy. PNPLA3 and TM6SF2 E167K genotypes were studied in 134 patients, 85 belonging to the
subgroup of the 100 biopsied subjects and 49 to the non- biopsied patients.
Systolic and diastolic blood pressures were measured twice on the same day, and the mean
values were used for analysis. The presence of hypertension was defined as having systolic
blood pressure over 140 mmHg or diastolic blood pressure over 90 mmHg more than twice or
as taking anti-hypertensive medication. Laboratory examinations included serum aspartate
aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase
(GGT), triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol,
total cholesterol, fasting glucose. Blood samples were collected from all participants after a
12-h overnight fast. Diabetes mellitus was diagnosed based on the American Association of
Diabetes criteria[31], whereas the MS defined according to the ATP III criteria[32, 33].
Cardiovascular risk was calculated using individual score developed in the Italian popula-
tion (Progetto Cuore). This was based on continuous values for some risk factors such as age,
total serum cholesterol, HDL and systolic blood pressure. Anti-hypertensive therapy is also
included in the assessment[34].
Average alcohol daily consumption (in grams of pure ethanol) was calculated by multiply-
ing frequency and amount, using beverage specific standard ethanol contents. In all patients,
daily alcohol intake was lower than 20 g in females and 30 g in males (confirmedby at least one
family member). In all patients, daily alcohol intake had to be lower than 20 g in females and
30 g in males to be included in the study.
According to smoking habits, individuals were categorized into current, former, or never-
smokers.
Ethic statement
The Institutional ReviewBoard “Comitato Etico Milano Area B, Fondazione IRCCSCa’
Granda OspedaleMaggiore Policlinico” reviewed and approved the study project (586 bis,
2014). This is the first part of the entire project.
All patients gave informed, written consent to participate in the study according to a proto-
col, conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Assessment of fatty liver by ultrasonography (US) and by Fatty Liver
Index (FLI)
FLI was calculated according with literature [35] in all NAFLD patients and correlated with
EAT.
Two experienced sonographers, who were unaware of the clinical characteristics of the
NAFLD patients, performed hepatic ultrasonography (US) in all subjects at enrollment using a
Philips (iU22 Healthcare, Bothell,WA, USA) and Esaote (MyLab70, Italy) device. The degree
EAT in NAFLD
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of hepatic steatosis was defined on the basis of accepted criteria (hepatorenal echo contrast,
liver brightness, deep attenuation, and vascular blurring [36, 37]) as mild (grade 1), moderate
(grade 2) and severe (grade 3).
Assessment of Carotid Atherosclerosis
Mean carotid arteries intima-media thickness (cIMT), an index of early atherosclerotic process,
was determined by high-resolution B-modeUS with a 7.5-MHz transducer, as describedprevi-
ously[38–40]. Values of cIMT represent the mean intima-media thickness on left and right
sides. For the common carotid arteries, images of the two sides were obtained 2 cm proximal to
the dilatation of the carotid bulb; for each subject, were performed 3 measurements on left and
right sides. Three experienced sonographers unaware of the clinical and biochemical character-
istics of NAFLD patients performed the evaluation of cIMT and carotid plaques. The inter-
rater correlation between the repetition of measurements of intima-media thickness was 0.96
mm (p<0.001), with similar averages of the 2 sets of readings. The imaging of the common
and internal carotid arteries of both sides are obtained in multiple longitudinal and transverse
planes. All regions of interest was studied to verify the presence of plaques that are defined as a
focal thickening>1.2 mm at the level of carotid artery.
Echocardiographic assessment
A single-experiencedcardiologist performed a focused two-dimensional transthoracic echocar-
diography using a commercially-available device (Esaote My lab 30 gold, Italy). Data acquisi-
tion was performedwith a 3.5-MHz transducer at a depth of 16 cm in the parasternal and
apical views. All recordings were digitally stored for off-line analyses by dedicated software,
and were later interpreted by the same cardiologist who performed the test. Conventional
echocardiographic parameters were measured according to the American Society of Echocardi-
ography (ASE) guidelines[41].M-mode echocardiograms of the left ventricle were recorded
from the parasternal long-axis view guided by two-dimensional image. The following parame-
ters were determined: left ventricular telediastolic internal diameter (LVIDd), interventricular
septum, and posterior wall thickness (PWTd). The relative wall thickness was also calculated
by the following formula [(2XPWTd)/LVIDd)], as an index of left ventricular geometry pat-
tern.When optimal orientation of LV M-mode ultrasound beam could not be obtained, cor-
rectly orientated linear dimensionmeasurements were performed using two-dimensional
imaging. The ejection fractionwas calculated at the apical four chamber views, the ejection
fractionwas calculated over five consecutive beats[42]. LV mass was calculated in grams using
the following formula: 0.8×(1.04[(LVID + IVS + PWT)3 − LVID3]) +0.6. LVM was normalized
for height to the 2.7 power (LVM/H2.7)[43].
Pulsed-wave Doppler images at the level of the mitral valve tips from apical four- chambers
two-dimensional views were obtained to measure flow velocities in the peak early diastolic (E-
wave) and peak late diastolic (A-wave) phase, and to calculate their ratio (E/A) as measurement
of diastolic filling [44]. Each value was obtained as the average of three measurements.
The most accurate evaluation of the epicardial fat of the right ventricle was obtained by
measuring EAT in the parasternal long- and short-axis views, with optimal cursor beam orien-
tation in each view. Maximum EAT, (the mean of at least three measures) was obtained during
end systole [45].
Non-invasive fibrosis evaluation
The FIB-4 was calculated according to literature[46], in particular the regression formula was:
age (years) x AST [U/l]/(platelets [109/l] x (ALT [U/l])1/2).
EAT in NAFLD
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The NAFLD Fibrosis Score (NFS) was calculated according to literature [47] in particular
the regression formula was = -1.675+0.037 x age (years)+ 0.094 x BMI (kg/m2) +1.13 x IGF/
diabetes (yes = 1,no = 0)+ 0.99 x AST/ALT ratio-0.013 x platelet (x109/l)- 0.66 x albumin (g/
dl).
Liver Histology
Of the entire cohort of 512 NAFLD in 100 patients US-guided liver biopsy was performed for
persistently abnormal liver biochemical tests, increased ferritin or, in patients with normal ami-
notransferases, in the presence of additional risk factors for NASH such as severe insulin resis-
tance, type 2 diabetes mellitus, and metabolic syndrome. Liver biopsy was performedwithin 4
months from cardiovascular assessment. The Kleiner classification[48] was used to grade stea-
tosis, lobular inflammation, and hepatocellular ballooning, and to stage fibrosis from 0 to 4.
NASH was considered to be present when steatosis, ballooning, and lobular inflammation were
all present.
Genotyping
The rs738409 C>G (I148M PNPLA3) and the rs58542926 C>T (E167K, TM6SF2) single-
nucleotide polymorphisms were assessed in duplicate by TaqMan 5’-nuclease assays (Life
Technologies, Carlsbad, CA). The success rate and reproducibility were>99%; random sam-
ples were confirmed by direct sequencing. The genotype distributions were in Hardy-Wein-
berg’s equilibrium and were performed in 134 patients.
Statistical analysis
To compare variables in men and women we used the chi-squared (for categorical variables)
and the Mann-Whitney or Kruskal-Wallis test (for quantitative variables).We then performed
two sets of multiple linear or logistic regression analyses: a) models adjusted only for age and
gender; and b) models fully adjusted for all the variables which were statistically significant in
age- and gender-adjusted models, but including only one of the variables with a similar role
(diabetes and fasting glucose, diastolic/systolic blood pressure and hypertension, BMI and
waist circumference). Statistical analyses were performedwith Stata 13 (StataCorp. 2013. Stata:
Release 13. Statistical Software. College Station, TX: StataCorp LP.)
Control group
Six hundred forty seven subjects from a large survey of the general population based volunteer
study for the evaluation of cardiovascular risk progression (the Progressione delle Lesioni Inti-
mali Carotidee (PLIC) study), representative of the entire PLIC cohort, in whom steatosis had
been ruled out by ultrasonography and b) were studied. Subjects with viral B and C hepatitis,
Wilson's disease, a1-antitrypsin deficiency, autoimmune hepatitis, genetic hemochromatosis,
and subjects using steatogenic drugs as well as subjects with a history of cardiovascular disease
(CVD) (myocardial infarction unstable angina, stroke, or cardiovascular revascularization)
were excluded. All Controls was analyzed and studied as the NAFLD patients.
Results
Characteristics of patients
Steatosis, as evaluated by US, was of grade 1, 2 and 3 in 230 (45%), 210 (41%) and 72 (14%) of
the overall series. Given the marked differences betweenmales and females, we analyzed char-
acteristics of the study cohort according to gender Table 1.
EAT in NAFLD
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Male patients were younger, had significantly lower BMI, but higher waist circumference,
similar prevalence of hypertension, diabetes and metabolic syndrome than females. The analy-
sis of cardiovascular parameters showed that male patients had a lower EAT, higher diastolic
Table 1. Characteristics of 512 patients with the overall series of NAFLD according to gender.
Variables NAFLD Female Male p
(n = 512) (n = 189) (n = 314)
Age (yrs) 61 ±13 63±10 57±12 0.0001
BMI (Kg/m2) 28.9 ±4 29.6±5 28.5±3 0.005
Waist circumference (cm) 100 ±10 97±11 101±9 0.001
Fasting glucose (g/L) 96 ±40 99±61 100±19 0.1
Total Cholesterol (mg/100 mL) 199±40 208±38 196±40 0.004
HDL Cholesterol (mg/100 mL) 54±15 60±15 50±13 0.0001
Triglycerides (mg/100 mL) 130 ±78 123±61 135±86 0.4
AST (U/L) 22± 15 23±13 29±18 0.0001
ALT (U/L) 23 ± 14 25±18 35±23 0.0001
GGT (U/L) 27± 43 32±41 49±45 0.0001
Systolic blood pressure (mmHg) 132 ±16 133±18 132±15 0.8
Diastolic blood pressure (mmHg) 81±9 81±9 80±10 0.6
Hypertension n, (%) 240 (47) 98 (52) 66 (46) 0.2
Diabetes n, (%) 82 (16) 32 (17) 47 (15) 0.4
Metabolic Syndrome n, (%) 215 (42) 85 (45) 125 (40) 0.9
CR score 10-year % 8.4±8 5.8±6 9.4±9 0.0001
Smoke n, (%) 189 (37) 60 (32) 125 (41) 0.05
Ultrasonographic steatosis grade n, (%)
1 230 (45) 110 (58) 120 (38) 0.001
2 205 (41) 72 (32) 143 (46)
3 70 (14) 20 (10) 50 (16)
Fatty Liver Index (FLI) 60±23 55.7±26 62.8±21 0.001
Cardiovascular parameter
cIMT (mm) 0.78±0.19 0.78±0.19 0.78±0.20 0.8
cplaques n, (%) 194 (38) 72 (38) 122 (39) 0.9
EAT (mm) 5.5±3.0 6.2±3.0 5.4±2.9 0.0001
E/A 0.97±0.33 0.91±0.32 1.01±34 0.0001
LVM 184±76 164±68 200±78 0.001
Non-invasive fibrosis score
FIB4 score 1.36±0.9 1.27±0.9 1.4±0.8 0.1
NFS score -1.55±1.4 -1.54±1.4 -1.56±1.4 0.9
Liver Histology°
NASH n, (%) 67/100 (67) 19/25 (76) 48/75 (64) 0.01
Steatosis grade 3 n, (%) 28/100 (28) 8/25 (32) 20/75 (27) 0.5
Fibrosis stage >2 n, (%) 32/100 (32) 13/25 (52) 19/75 (25) 0.01
Genotype*
PNPLA3 genotype GG n (%) 26/134 (19) 11/36 (31) 15/106(14) 0.4
TM6SF2 genotype EK+K, n (%) 29/134 (22) 5/34 (15) 24/99 (24) 0.2
mean ±SD; cIMT carotid Intima-media thickness, cplaques = carotid plaques, EAT = epicardial adipose tissue thickness, LVM = left ventricular mass, CR
score = Cardiovascular risk score
°Liver histology available in 100 patients
*PNPLA3 and TM6SF2 genotypes available in 134 patients
doi:10.1371/journal.pone.0162473.t001
EAT in NAFLD
PLOS ONE | DOI:10.1371/journal.pone.0162473 September 14, 2016 6 / 19
dysfunction (E/A), and LV mass, and, limited to patients with available liver histology, also a
lower prevalence of NASH and fibrosis stage>2.
In our seriesmost of the NAFLD women (86%) were over 50 years old. To avoid the possible
role of menopausal status in the analyses we evaluated the degree of liver damage in women
according to age> or< 50 years. Non-invasive fibrosis score significantly differed in women
below or over 50 years (FIB-4 0.78±0.5 vs 1.34±0.7, p = 0.0001, and NFS -3.06±0.97 vs -1.36±1.3,
p = 0.0001), while EAT (5.7±2.5 vs 6.2±3, p = 0.2), fatty liver index (51.4±30 vs 55.0±26, p = 0.7),
fibrosis>2 (30%vs 61%,p = 0.2) and NASH (85% vs 72%, p = 0.3) did not differ significantly.
The characteristics of patients according to tertiles of EAT are presented in Table 2. A sig-
nificant higher BMI and waist circumference, prevalence of diabetes, metabolic syndrome, car-
diovascular and liver damage were observed across the tertiles.
When we analyzed the characteristics of NAFLD in the subgroup of the 100 biopsy-proven
and in the subgroup with PNPLA3 and TM6SF2 genotyping, as expected, patients who under-
went liver biopsy had worse metabolic and liver profile while the parameters of the genotyped
patients were similar to that of the entire cohort.
Patients with NAFLD had a significant higher levels of EAT that control subjects of general
population in addition to all others metabolic, anthropometric, and cardiovascular damage
parameters (S1 Table).
Association of EAT with severity of liver steatosis, by US and Fatty Liver
Index, (FLI) and with metabolic parameters
The association between EAT and US degree of steatosis at univariate analysis is shown in Fig
1 (p<0.001 for trend).
Results of the association between epicardial adipose tissue (EAT, mm) metabolic and clini-
cal variable, ultrasonographic steatosis grades and FLI are reported in Table 3. Age, male gen-
der, BMI, diastolic blood pressure, the degree of ultrasonographic steatosis, FLI and the use of
statin were independently associated with EAT. Waist circumference used instead of BMI in
multivariable model was found independently associated with EAT (coefficient 0.06, 95% C.I.
0.03–0.09, p = 0.0001).
The multivariate analysis of the association of EAT level higher 4 mm (the median values of
control subjects without steatosis) in the overall series including NAFLD patients and Controls
indicated that EAT was significantly associated with age, female gender, BMI, waist circumfer-
ence, smoke habits, steatosis, cplaques and E/A (S2 Table).
Relationship between cardiovascular damage (cIMT, cplaques, E/A) and
metabolic risk factors including EAT
The associations between EAT and cardiovascular damage parameters (cIMT, cplaques, E/A)
at univariate analysis are shown in Fig 2. A significant linear increase of cIMT and risk of pla-
ques and a decrease of E/A with increasing EAT was present.
The multiple linear (cIMT, E/A) and logistic regression (cplaques) analyses, age- and gen-
der-and fully adjusted models are shown in Table 4. cIMT in the fully adjusted model was inde-
pendently associated with age, hypertension, diabetes, FLI and smoking habits, cplaques with
age, BMI, EAT and hypertension, and E/A with age, diabetes, FLI and hypertension.
Patients with cplaques had significant higher values of EAT than those without (6.1±3 v.s.
5.0±2.9, p = 0.0001).
In addition we evaluated the association between EAT and cplaques separately in men and
women, the O.R. in man was 1.19 (95% C.I. 1.05–1.35, p = 0.005) and in woman 1.04 (95% C.I.
091–1.19, p = 0.55), however p for gender-EAT interaction was not significant (p = 0.14).
EAT in NAFLD
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Table 2. Characteristics of 512 patients with NAFLD divided according to EAT tertile.
Variables NAFLD EAT EAT EAT p^
(n = 512) Tertile1 Tertile 2 Tertile 3
(<4.1 mm) (4.1–6.8 mm) (  6.9 mm)
Age (yrs) 61 ±13 57±15 58±13 62±12 0.004
BMI (Kg/m2) 28.9 ±4 27.3±3.7 29.1±3.5 30.3±4.4 0.0001
Waist circumference (cm) 100 ±10 96±10 101±9 103±11 0.0001
Fasting glucose (g/L) 96 ±40 96±15 97±21 106±22 0.0001
Total Cholesterol (mg/100 mL) 199±40 202±40 197±42 201±37 0.6
HDL Cholesterol (mg/100 mL) 54±15 55±17 52±14 55±14 0.8
Triglycerides (mg/100 mL) 130 ±78 132±88 132±79 126±65 0.4
AST (U/L) 22± 15 26±16 27±16 26±18 0.9
ALT (U/L) 23 ± 14 32±23 32±24 34±17 0.1
GGT (U/L) 27± 43 40±38 44±43 42±49 0.6
Systolic blood pressure (mmHg) 132 ±16 128±13 133±16 135±18 0.0001
Diastolic blood pressure (mmHg) 81±9 78±10 81±8 83±10 0.0001
Hypertension n, (%) 240 (47) 72 (42) 79 (46) 89 (52) 0.04
Diabetes n, (%) 82 (16) 13(8) 28 (16) 41(24) 0.0001
Metabolic Syndrome n, (%) 215 (42) 52 (31) 68 (40) 95(56) 0.0001
CR score 10-year % 8.4±8 7.2±8.1 8.3±8.3 8.7±7.6 0.1
Smoke n, (%) 189 (37) 57(34) 64(38) 71(42) 0.1
Ultrasonographic steatosis grade n, (%)
1 230 (45) 92 (55) 74 (44) 64 (38) Ref
2 205 (41) 61 (36) 69 (41) 75 (44) 0.015
3 70 (14) 15 (9) 25 (15) 30 (18) 0.003
Fatty Liver Index (FLI) 60±23 52±25 61±22 66±22 0.0001
Cardiovascular parameter
cIMT (mm) 0.78±0.19 0.75±0.20 0.80±0.20 0.79±18 0.04
cplaques n, (%) 194 (38) 52 (31) 66 (39) 76 (45) 0.004
E/A 0.97±0.33 1.04±0.38 0.99±0.34 0.88±0.26 0.0001
LVM 184±76 180±73 187±69 185±85 0.6
Non-invasive fibrosis score
FIB4 score 1.36±0.9 1.32±1.0 1.32±0.8 1.43±0.9 0.3
NFS score -1.55±1.4 -1.83±1.3 -1.59±1.4 -1.22±1.4 0.0001
Liver Histology°
NASH n, (%) 67/100 (67) 14/28 (52) 31/41 (76) 22/31 (88) 0.005
Steatosis grade n, (%)
1 25/100 (25) 10/28 (36) 10/41 (24) 5/31(16) Ref
2 47/100 (47) 12/28 (43) 20/41 (49) 15/31 (48) 0.17
3 28/100 (28) 6/28 (21) 11/41 (27) 11/31 (35) 0.08
Fibrosis stage >2 n, (%) 32/100 (32) 2/28 (7) 13/41 (32) 17/31(55) 0.0001
Genotype*
PNPLA3 genotype GG n (%)* 26/134 (19) 9/43 (20) 8/56 (14) 9/35 (26) 0.1
TM6SF2 genotype EK+K, n (%)* 29/134 (22) 10/45(22) 14/56(25) 5/33(15) 0.5
° Liver histology available in 100 cases
* PNPLA3 and TM6SF2 genotypes available in 134 cases
^ p = for trend
doi:10.1371/journal.pone.0162473.t002
EAT in NAFLD
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Relationship between non-invasive fibrosis score and EAT
To evaluate the relationship between EAT and NFS we performed a linear regression analysis
and we found a significant positive correlation (slope +0.4 mmC.I.0.19–0.60, p<0.001) for
each unit increase of NFS.We made the similar analysis with FIB4 (log-e transformation
because of the highly skewed distribution) and we also found a significant correlation with
EAT (slope +0.58, C.I. 0.03–1.14, p = 0.039).
Relationship between histological liver damage (presence of NASH and
fibrosis >2) and metabolic risk factors including EAT
The relationship was evaluated in the 100 patients who underwent liver biopsy.
A logistic regression analysis, age- and gender-and fully adjusted model is shown in Table 5.
steatosis of grade 3 was independently associated only with age; NASH was independently
associated with EAT and diabetes and significant fibrosis (>2) with waist circumference, EAT
and diabetes.
When patients were stratified according to the presence of fibrosis (stage F0-F2, n = 61
(61%), F3-F4, n = 39 (39%)), EAT values were higher in patients with more severe fibrosis (6.8,
5.5–7.4 vs. 4.9, 3.1–6.7 mm, in F3-F4 and F0-F2 respectively; p = 0.02).
Fig 1. Association between EAT and US degree of steatosis. EAT according to US fatty liver grade, (p<0.001 for trend).
doi:10.1371/journal.pone.0162473.g001
EAT in NAFLD
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The mean value of EAT in patients with or without NASH (5.9± 2.5 vs 4.0±, 2.4,p = 0.001)
and with or without fibrosis>2 (6.9±2.3 vs 4.7±2.5, p = 0.0001) was significantly higher.
Association between EAT, PNPLA3 and TM6SF2 polymorphisms
In Tables 1 and 2 are reported results of the prevalence of PNPLA3 and TM6SF2 polymor-
phisms, evaluated in 134 patients with NAFLD. We did not observe significant differences of
EAT value in patients homozygous or heterozygous for the two polymorphisms. Patients with
CG+GG genotypes of PNPLA3 and patients with EK+K genotypes of TM6SF2 had higher
prevalence of NASH (70 and 76% vs 30 and 24%) and of Fibrosis 2 (53 and 71% vs 47 and
29) in comparison of patients wild type, but data did not reach statistical significance possibly
for the low number of cases.
Discussion
In the present study we analyzed in a large series of subjects with NAFLD whether EAT corre-
lates with cardiovascular and liver damage and we demonstrated that EAT is associated both
with subclinical atherosclerosis and NASH and significant fibrosis independently of other met-
abolic confounders (BMI, waist circumference, diabetes, hypertension....) and that there is a
significant relationship between increased value of EAT and cardiovascular and liver damage
and metabolic alterations. The relationships between EAT, and cardiovascular damage has
been recently reported in selected patients series[16, 27–30, 49–52], however this is the first
study, to our knowledge, performed in a large series of well characterizedNAFLD patients in
whom we demonstrated a significant correlation between EAT values and atherosclerosis as
documented by the independent association with cplaques. Previous observations suggested an
Table 3. Association between epicardial adipose tissue (EAT, mm) metabolic and clinical variables and ultrasonographic steatosis grades.
Results of multiple linear regression analyses, age- and gender-adjusted and fully adjusted*.
Age and gender adjusted model Fully adjusted model*
Variables Coefficient 95% C.I. P Coefficient 95%C.I. P
Age (yrs) - - - 0.21 0.11, 0.42 0.04
Female gender - - - 0.47 0.20,0.74 0.001
BMI (Kg/m2) 0.2 0.1, 0.3 0.0001 0.18 0.12, 0.24 0.0001
Waist circumference (cm)° 0.08 0.06, 0.11 0.0001 0.06 0.03, 0.09 0.0001
Fasting glucose (g/L) 0.23 0.10, 0.37 0.001 Not included - -
Systolic blood pressure (mmHg) 0.29 0.12, 0.45 0.01 -0.30 -0.33,0.17 0.7
Diastolic blood pressure (mmHg) 0.63 0.36, 0.91 0.0001 0.46 0.11,0.82 0.009
Hypertension 0.13 -0.41, 0.68 0.6
Diabetes 1.1 0.37, 1.79 0.003 0.54 -0.17,1.2 0.14
Metabolic Syndrome 1.1 0.53, 1.63 0.0003 Not included - -
Smoke 0.76 0.22, 1.31 0.006 0.45 -0.07,0.50 0.09
Ultrasonographic Steatosis grade
Reference: 1 Ref Ref - - -
2 1.1 0.47, 1.58 0.0001 0.6 -0.02,1.3 0.058
3 1.8 1.04, 2.59 0.001 1.42 0.4, 2.4 0.007
Fatty liver index (FLI) 0.04 0.02, 0.05 0.0001 0.02 0.01, 0.04 0.0001
Statin use 0.6 -0.03, 1.3 0.06 0.8 0.06,1.5 0.03
* Fully adjusted = each variable adjusted for the others except when indicated.
° In the fully adjusted model we included either waist circumference or BMI
doi:10.1371/journal.pone.0162473.t003
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association between epicardial adiposity and the presence and severity of coronary artery dis-
ease[17–19, 24, 53], and more recently with vascular stiffness, another subclinical sign of
carotid atherosclerosis [29, 54]. Thus EAT contributing to the development and progression of
atherosclerosis, may represent a measurable risk factor and in future a modifiable therapeutic
target as recently suggested [55].
Iacobellis et al. [28] showed that obese patients with severe fatty liver infiltration have a high
amount of epicardial fat accumulation, we confirm these results in a large series of non-obese,
overweight NAFLD subjects. In addition we observed a parallel trend between EAT and liver
fat suggesting that ectopic fat may be simultaneously present in different organs inducing
organ specific damage, as recently hypothesized[56, 57]. In line with this is the observation that
subclinical vascular damage, defined as an increase of cIMT, paralleled the severity of steatosis
evaluated at ultrasonography and the fatty liver index, reported to be a good indicator of
hepatic steatosis [35].
We also showed an independent association between EAT, NASH and significant liver
fibrosis, confirming recent results [30, 49]. Interestingly, in these patients we observeda signifi-
cant independent association between EAT and atherosclerosis and between EAT and liver
damage, supporting the hypothesis that the cytokines/adipocytokinessecreted by epicardial
Fig 2. Association between EAT and cardiovascular parameters. EAT (unit) and cIMT (panel A), coefficientβ: 0.005, (95% C.I. 0.001,
0.009), p = 0.007, EAT and cplaques (panel B) O.R. 1.10 (95%C.I. 1.04–1.18), p<0.0001, EAT and E/A (panel C) coefficient β -0.02, (95%
C.I. -0.03, -0.01), p = <0.0001).
doi:10.1371/journal.pone.0162473.g002
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Table 4. Association of parameters of cardiovascular damage (cIMT (mm), cplaques and E/A) with EAT and metabolic, clinical variables and ultra-
sonographic steatosis grades. Results of multiple linear (cIMT, E/A) and logistic regression (cplaques) analyses, age- and gender-adjusted and fully
adjusted models*.
Age and gender adjusted model Fully adjusted model *
Variables Coefficient 95% C.I. P Coefficient 95%C.I. P
cIMT cIMT
Age (yrs) - - - 0.04 0.03, 0.06 0.0001
Male gender - - - -0.19 -0.04, 0.05 0.18
BMI (Kg/m2) 0.005 0.0001, 0.008 0.03 0.004 -0.007, 0.008 0.9
Waist circumference (cm) 0.002 0.0007, 0.004 0.005 0.002 0.0002, 0,004 0.03
EAT (mm) 0.0008 -0.004, 0.006 0.7 -0.004 -0.011, 0.002 0.2
Fasting glucose (g/L) 0.01 0.002,0.02 0.02 Not included - -
Hypertension 0.06 0.03, 0.09 0.001 0.05 0.01, 0.09 0.009
Diabetes 0.07 0.03, 0.11 0.002 0.05 0.003,0.1 0.04
Metabolic Syndrome 0.02 -0.09, 0.065 0.1 - - -
Smoke 0.04 0.007,0.78 0.02 0.05 0.002, 0.09 0.04
Ultrasonographic Steatosis grade
1 Ref Ref Ref Ref
2–3 1.14 0.02,1.25 0.05 -0.01 0.2, -0.04 0.2
Fatty liver index (FLI) 0.001 0.004, 0.007 0.0008 0.001 0.0001, 0.002 0.02
Statin use 0.03 -0.01, 0.07 0.2 0.04 -0.009, 0.08 0.1
cplaques cplaques
O.R. 95%C.I. P O.R. 95%C.I. P
Age - - - 2.3 1.73, 2.80 0.0001
Male gender - - - 0.0 0.40,1.06 0.09
BMI (Kg/m2) 0.98 0.93,1.04 0.6 0.93 0.88,1.0 0.03
Waist circumference (cm)° 1.01 0.99, 1.03 0.2 0.97 0.94, 0.99 0.04
EAT (mm) 1.08 1.01,1.17 0.02 1.10 1.0–1.12 0.02
Smoke 1.4 0.90, 2.1 0.1 - - -
Diabetes 1.5 0.88, 2.6 0.1 0.99 0.54,1.8 0.98
Hypertension 1.8 1.18, 2.7 0.006 2.1 1.2, 3.5 0.005
Metabolic Syndrome 0.88 0.56,1.34 0.6 - - -
Ultrasonographic Steatosis grade
1 Ref Ref - - -
2–3 3.6 0.89,15 0.07 - - -
Fatty liver index 0.99 0.98, 1.1 0.5 - - -
Statin use 0.5 0.1,1.0 0.03 1.1 0.6, 2.03 0.7
E/A E/A
O.R. 95%C.I. P O.R. 95% C.I. P
Age (yrs) - - - -0.09 -0.11, -0.06 0.0001
Male gender - - - 0.03 -0.04, 0.11 0.4
BMI (Kg/m2) -0.007 -0.013, 0.004 0.04 0.003 -0.009, 0.2 0.6
Waist circumference (cm)° -0.003 -0.007,-0.001 0.008 0.003 -0.02, 0.008 0.2
EAT (mm) -0.12 -0.021, -0.003 0.007 -0.008 -0.02, 0.11 0.1
Diabetes -0.11 -0.18,-0.03 0.005 -0.01 -0.02, 0.03 0.005
Hypertension -0.08 -0.12, -0.017 0.01 -0.05 -0.11, 0.1 0.04
Metabolic Syndrome -0.07 -0.13,-0.16 0.01 Not included - -
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adipose tissue, acting as a paracrine tissue, favor the local inflammation in vessel and liver,
being responsible for the damage of these districts. The inflammatory state that characterizes
NAFLD/NASH might be able to act systemically, affecting the homeostasis of different organs
as demonstrated for systemic atherosclerosis [58] and kidney [59]. Moreover in our series of
NAFLD patients when we performed the analysis adjusted for age and gender, which was nec-
essary because of the strong effect of age and the differences between genders, we observed a
significant association between EAT and metabolic syndrome, as extensively reported in litera-
ture[60]. These results were confirmed in fully adjusted multivariate analysis in which the sin-
gle components of metabolic syndrome were not included (data not shown).
In our study, given the large series of subjects analyzed, we could arbitrarily define a value of
EAT (  6 mm) able to defineNAFLD patients at higher risk of more severe vascular and liver
damage. This value could represent an implement to identify subjects requiring a more intensive
hepatic and vascular diagnostic approach and follow-up, and represent an additional tool for the
stratification of cardiovascular risk in general population as recently proposed by our group[61].
This is reinforced by the results obtained by comparing the value of EAT of NAFLD patients with
those of a control group of general population in which the level of EAT was significantly lower.
Finally we analyzed whether polymorphisms of PNPLA3, the most important known
genetic determinant of NAFLD and highly associated with severity of hepatic damage and
fibrosis, influence the entity of EAT, but we did not find any significant association between
this genetic marker and EAT, carotid atherosclerosis (cIMT or cplaques) despite patients who
carriedGG genotype had more severe liver disease. However, while the role of PNPLA3 in the
severity of liver injury has been well documented, its role on vascular damage is still debated
[62, 63], and needs to be validated in a larger cohort of subjects.We obtained similar results
when we evaluated the TM6SF2 polymorphisms. In fact we did not observe any difference in
the prevalence of TM6SF2 polymorphisms at increasing values of EAT. However we cannot
rule out that this may be due to the relatively small number of patients studied.
Strengths of this study include the large series of well characterizedNAFLD subjects who
had abdominal ultrasonographic, carotid and heart assessment performed at the same time,
thereby allowing to compare fat accumulation in different sites, and to analyze their association
with the cardio-metabolic status and severity of liver damage.
Limitations were related to the lack of direct assessment of visceral fat accumulation by
NMR, which was precluded by the large series of patients considered. Furthermore, liver biopsy
was available in a minority of NAFLD patients, due to the study design and ethical reasons,
however if the reference values of EAT ( 6 mm) will be confirmed in larger series of biopsy
proven NAFLD, EAT could represent a non invasive marker of inflammation and used to bet-
ter characterize the presence of NASH. Finally, we could not quantify inflammatorymolecules
Table 4. (Continued)
Age and gender adjusted model Fully adjusted model *
Variables Coefficient 95% C.I. P Coefficient 95%C.I. P
1 Ref Ref - - - -
2–3 -0.02 -0.17, 0.11 0.9 - - -
Fatty liver index (FLI) -0.002 -0.003, -0.001 0.0003 -0.003 -0.005, -0.001 0.004
Statin use -0.01 -0.08, 0.06 0.7 0.06 -0.7, 0.08 0.8
* Fully adjusted = each variable adjusted for the others except when indicated.
cIMT carotid Intima-media thickness, cplaques = carotid plaques, EAT = epicardial adipose tissue thickness
° In the fully adjusted model we included either waist circumference or BMI
doi:10.1371/journal.pone.0162473.t004
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(e.g., tumor necrosis factor-alpha, cytokines, adipokines. . .) released by epicardial fat which
potentially could have helped to explain the relationship among fatty liver, EAT, and cardio-
vascular damage.
In conclusion, our results suggest that epicardial fat deposition is part of the same metabolic
disorders associated with the development of fatty liver in individuals with insulin resistance.
High EAT may represent a marker of the severity of this condition, as highlighted by its associ-
ation with NASH, liver fibrosis and cplaques, and may also be involved in the progression of
target organ damage, especially at the level of heart, vessels and liver.
We further emphasize the need for non-invasive cardiovascular assessment and for a more
accurate study of liver damage in patients with steatosis given the high risk of developing fibro-
sis. Longitudinal studies are required to establish whether EAT represents an independent
Table 5. Association of parameters of liver damage (steatosisgrade 3, NASH and fibrosis>2) and EAT and metabolic and clinical variables. Results
of logistic regression analyses age- and gender-adjusted and fully adjusted models (analysis performed in 100 patients with liver histology).
Age and gender adjusted model Fully adjusted model*
Variables Coefficient 95% C.I. p Coefficient 95%C.I. P
Steatosis grade 3 Steatosis grade3
Age (yrs) - - - 0.8 0.7,0.9 0.02
Male gender - - - - - -
BMI (Kg/m2) 1.2 0.99,1.4 0.06 - - -
Waist circumference (cm)° 1.04 0.95,1.1 0.4 - - -
EAT (mm) 1.1 0.89,1.2 0.5 - - -
ALT (UI) 0.04 0.01,0.08 0.02 1.4 1.003,1.88 0.05
Diabetes 4.4 0.9, 24 0.08 - - -
Metabolic Syndrome 1.4 0.5,3.9 0.5 - - -
Fatty liver Index 1.0 0.98, 1.03 0.7 - - -
Statin use 1.04 0.2,4.5 0.9 - - -
NASH NASH
Age (yrs) - - - 0.24 0.03, 0.06 0.4
Male gender - - - 4.90 0.68,18 0.13
BMI (Kg/m2) 0.9 1.0, 1.1 0.08 1.07 0.92,1.3 0.3
Waist circumference (cm)° 1.1 0.9, 1.0 0.1 - - -
EAT (mm) 1.3 1.1, 1.6 0.01 1.70 1.1,2.0 0.01
Diabetes 3.6 1.0, 17 0.05 35 0.99, 1.0 0.054
Fatty liver index 1.01 0.98, 1.04 0.3 1.02 0.96, 1.08 0.4
Statin use 1.36 0.3, 6.1 0.6 - -
Fibrosis >2 Fibrosis >2
Age (yrs) - - - 1.04 0.4, 8.9 0.5
Male gender - - - 1.70 0.50, 2.09 0.9
BMI (Kg/m2) 1.1 1.0, 1.1 0.03 0.90 0.7,1.2 0.6
Waist circumference (cm)° 1.1 1.1, 1.2 0.004 1.10 1,1.2 0.05
EAT (mm) 1.4 1.1, 1.8 0.04 1.46 1.06, 2.0 0.02
Diabetes 1.8 0.6, 5.2 0.2 9.5 1.4, 67 0.02
Steatosis
Fatty liver index 1.1 1.0,1.6 0.04 1.02 0.96,1.08 0.4
Statin use 1.7 0.5,6.1 0.4 - - -
* Fully adjusted = each variable adjusted for the others except when indicated.
° In the fully adjusted model we included either waist circumference or BMI
doi:10.1371/journal.pone.0162473.t005
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predictor of cardiovascular events, the main cause of death of patients with NAFLD, and
whethermay help to identify patients at risk of progressive disease.
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